Fri, January 24, 2025
Sun, December 22, 2024
[ Sun, Dec 22nd 2024 ]: Travel + Leisure
Eden Rock - St. Barths
Sat, December 21, 2024
Fri, December 20, 2024
Thu, December 19, 2024
Wed, December 18, 2024
Tue, December 17, 2024
Mon, December 16, 2024
Sun, December 15, 2024
Sat, December 14, 2024
Fri, December 13, 2024
Thu, December 12, 2024
Wed, December 11, 2024
Tue, December 10, 2024
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ]: Travel + Leisure
The Best Hotels in Dubai
Sun, December 8, 2024
Sat, December 7, 2024
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ]: Travel + Leisure
Letter From the Editor
Thu, December 5, 2024
Wed, December 4, 2024
Tue, December 3, 2024
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ]: Hubert Carizone
Travel of Tomorrow
[ Mon, Dec 02nd 2024 ]: Hubert Carizone
Caribbean Calling
Sun, December 1, 2024
Sat, November 30, 2024
Fri, November 29, 2024
Thu, November 28, 2024
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ]: Hubert Carizone
Cond Nast Traveler
Tue, November 26, 2024
Mon, November 25, 2024
Sun, November 24, 2024
Fri, November 22, 2024
Thu, July 2, 2009
Thu, March 19, 2009

Stellar Biotechnologies Files U.S. Patent Application for KLH Manufacturing Innovations

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. plication-for-klh-manufacturing-innovations.html
  Print publication without navigation Published in Stocks and Investing on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

December 04, 2012 08:55 ET

Stellar Biotechnologies Files U.S. Patent Application for KLH Manufacturing Innovations

PORT HUENEME, CA--(Marketwire - Dec 4, 2012) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (TSX VENTURE: [ KLH ]) (PINKSHEETS: [ SBOTF ]) (FRANKFURT: RBT), the world leader in sustainable manufacture of GMP-grade Keyhole Limpet Hemocyanin (KLH), today announced that the Company has submitted a patent application to the U.S. Patent and Trademark Office for new innovations related to the Company's Keyhole Limpet Hemocyanin ("KLH") technology. The patent application included claims for pharmaceutical grade compositions of matter, advanced manufacturing processes, and methods of use in a wide range of therapies.

KLH is a naturally derived protein typically used as a carrier protein in therapeutic vaccines or a stimulant in immunotoxicology applications.

"Stellar Biotechnologies is the only company with sustainable, environmentally sound manufacturing processes for pharmaceutical grade KLH," said John Sundsmo, Ph.D., V.P. of Research and Intellectual Property. "In addition to our existing protection and pending applications, this new patent intellectual property further secures our leadership in KLH processing and quality innovations."

For more information:

Visit Stellar Biotechnologies website at [ www.StellarBiotech.com ] and the KLH knowledge base KLH Site™ at [ www.KLHSite.com ].

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX VENTURE: [ KLH ]) (PINKSHEETS: [ SBOTF ]) (FRANKFURT: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of [ http://stellarbiotechnologies.com/investors/news_releases/ ]

Forward-Looking Statements

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.